- Home
- STEW vs TSHA Comparison
STEW vs TSHA Comparison
Compare STEW & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STEW | TSHA |
|---|---|---|
| Founded | 1972 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | STEW | TSHA |
|---|---|---|
| Price | $18.38 | $4.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $10.56 |
| AVG Volume (30 Days) | 84.5K | ★ 2.6M |
| Earning Date | 01-01-0001 | 02-25-2026 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | N/A | ★ $6,310,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.34 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.97 | $1.05 |
| 52 Week High | $14.94 | $6.02 |
Technical Indicators
Market Signals| Indicator | STEW | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 57.70 | 45.77 |
| Support Level | $18.05 | $4.40 |
| Resistance Level | $18.41 | $4.86 |
| Average True Range (ATR) | 0.19 | 0.26 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 90.98 | 30.34 |
Price Performance
Historical ComparisonAbout STEW SRH Total Return Fund Inc.
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.